Exchange: NASDAQ·Updated 07:59 PM EST

MTSR Metsera Inc

$70.50
$0.25
(0.35%)
Today
Closed $70.50
$0.1813
(0.26%)
After Hours
Reported EarningsJul 28
Mkt Cap$7.43B
Vol27.91M

About MTSR

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.
51

Neutral Sentiment

How do you feel about MTSR?

Advertisement|Remove ads.